SEHK:1060
SEHK:1060Entertainment

Damai Entertainment Holdings (SEHK:1060): Exploring Valuation After Doubling Its Connected Transaction Cap for Drama Expansion

Damai Entertainment Holdings (SEHK:1060) has increased its annual cap for connected transactions, raising the limit from RMB100 million to RMB200 million. This change follows higher-than-expected business volume, largely due to the company’s growing drama series production. See our latest analysis for Damai Entertainment Holdings. Damai Entertainment’s decision to boost transaction limits comes after an eventful year for the business, with the stock’s share price rising a remarkable 91.4%...
SEHK:863
SEHK:863Capital Markets

Will OSL Group's (SEHK:863) Stablecoin Expansion Redefine Its International Strategy?

OSL Group Limited recently presented at the Morgan Stanley 24th Asia-Pacific Summit in Singapore, sharing updates on their international strategy and digital asset initiatives. Hong Kong-listed OSL Group has announced the launch of stablecoin payment services for wholesale clients in Australia, highlighting opportunities arising from evolving digital asset regulations in that market. We'll explore how OSL Group’s move to introduce stablecoin payments in Australia could influence its growth...
SEHK:1428
SEHK:1428Capital Markets

Why Did Bright Smart Securities (SEHK:1428) Boost Profits Despite Lower Revenue This Half-Year?

Bright Smart Securities & Commodities Group Limited has announced its half-year earnings for the period ended September 30, 2025, reporting revenue of HK$630.56 million and net income of HK$326.92 million. While revenue edged slightly lower compared to the same period last year, the company succeeded in lifting both net income and earnings per share. With improved profitability despite lower revenue, we'll explore what these results mean for Bright Smart Securities & Commodities Group's...
SEHK:839
SEHK:839Consumer Services

A Look at China Education Group Holdings (SEHK:839) Valuation Following Strong Annual Sales and Earnings Growth

China Education Group Holdings (SEHK:839) released its annual earnings report, highlighting sharp growth in both sales and net income for the year ended August 31, 2025. The company’s improved financial metrics are attracting fresh attention from investors. See our latest analysis for China Education Group Holdings. Shares of China Education Group Holdings have seen a recent uptick following the latest earnings release, with a 1.82% gain in the last day and 4.87% over the past week. Despite...
SEHK:2282
SEHK:2282Hospitality

A Closer Look at MGM China Holdings (SEHK:2282) Valuation After JPMorgan Highlights Stock in 2026 Outlook

JPMorgan’s newly released 2026 outlook report has highlighted MGM China Holdings (SEHK:2282) as one of its preferred stocks for the first quarter, drawing attention to the company’s performance and potential in Greater China’s gaming and lodging sector. See our latest analysis for MGM China Holdings. After JPMorgan’s positive nod, MGM China Holdings has enjoyed robust momentum, with the share price up 63.89% year-to-date and a stellar 76.7% total shareholder return over the past year...
SEHK:3690
SEHK:3690Hospitality

Meituan (SEHK:3690) Quarterly Net Loss Challenges Profitability Narrative Despite Revenue Growth

Meituan (SEHK:3690) reported Q3 2025 revenue of ¥95.5 billion. Net income (excluding extraordinary items) slipped to a loss of ¥18.6 billion. Over the past year, the company saw total revenue rise from ¥322.8 billion in Q3 2024 to ¥362.4 billion in Q3 2025. Earnings swung from a profit of ¥31.8 billion to a loss of ¥2.0 billion on a trailing twelve-month basis. Margins compressed this quarter, putting the focus on the company’s path to profitability and future growth drivers. See our full...
SEHK:673
SEHK:673Healthcare

China Health Group (SEHK:673) Losses Deepen, Undercutting Bullish Value Narrative

China Health Group (SEHK:673) has released its H1 2026 financials, reporting revenue of HK$20.26 million and a basic EPS of -0.1027 HKD. Looking back, the company’s revenue was HK$18.68 million in H1 2025 and HK$31.66 million in H2 2024. Basic EPS figures were -0.0359 HKD and -0.0525 HKD for these periods. Persistently negative earnings reflect margins under pressure, raising ongoing concerns about the company’s ability to achieve profitability. See our full analysis for China Health...